All In Biotech

Drug Trial Radar · NCT02251275

Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease

A Phase 3b, Multi-center, Open-label Trial to Evaluate the Long Term Safety of Immediate-release Tolvaptan (OPC-41061, 30 mg to 120 mg/Day, Split Dose) in Subjects With Autosomal Dominant Polycystic Kidney Disease

Last checked: Nov 20, 2026Latest source record: Nov 27, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,803

Actual

Start

Oct 17, 2014

Primary completion

Nov 9, 2018

Study completion Nov 9, 2018

Sponsor

Sponsor type
Industry
First posted
Sep 29, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the trial was to evaluate and describe the long term safety of tolvaptan in participants with autosomal dominant polycystic kidney disease (ADPKD).

Conditions

  • Polycystic Kidney, Autosomal Dominant

Interventions

  • TolvaptanDrug

    Tolvaptan tablets (15 or 30 mg) self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number Of Participants Reporting Treatment-Emergent Adverse Events (TEAEs)Time frame: Baseline through end of treatment (up to 42 months) and follow-up 7 days posttreatment(+ 7 days)

Locations

210 sites in 20 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Huntsville, Alabama

  • Site not named

    Mobile, Alabama

  • Site not named

    Phoenix, Arizona

  • Site not named

    Tempe, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    La Jolla, California

  • Site not named

    Los Angeles, California

  • Site not named

    Los Angeles, California

  • Site not named

    San Francisco, California

  • Site not named

    Stanford, California

  • Site not named

    Aurora, Colorado

  • Site not named

    Denver, Colorado

  • Site not named

    Denver, Colorado

  • Site not named

    New Haven, Connecticut

  • Site not named

    Hudson, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Ocala, Florida

  • Site not named

    Port Charlotte, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Augusta, Georgia

  • Site not named

    Meridian, Idaho

  • Site not named

    Chicago, Illinois

  • Site not named

    Chicago, Illinois

  • Site not named

    Kansas City, Kansas

  • Site not named

    Wichita, Kansas

  • Site not named

    Baton Rouge, Louisiana

  • Site not named

    Baltimore, Maryland

  • Site not named

    Baltimore, Maryland

  • Site not named

    Greenbelt, Maryland

  • Site not named

    Rockville, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Springfield, Massachusetts

  • Site not named

    Detroit, Michigan

  • Site not named

    Grand Rapids, Michigan

  • Site not named

    Kalamazoo, Michigan

  • Site not named

    Pontiac, Michigan

  • Site not named

    Roseville, Michigan

Showing 40 of 210 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.